A drug discovery company combining high-throughput synthetic biology with in-depth biological profiling to address complex disease targets.
Octant has developed a novel drug discovery platform for identifying compounds with desirable activity profiles in complex, disease-relevant targets. Their approach uses high throughput synthetic biology and cellular engineering to create libraries of receptor-reporters to quantify drug effects on up to 100s of receptors or pathways simultaneously. By performing drug discovery through this massively parallel experimental lens, Octant can see problems and solutions that are overlooked by traditional means (like off-target effects) and tackle drug development challenges that have prevented others from reaching or succeeding in the clinic. They have initially prioritized two therapeutic strategies in GPCR polypharmacology and small molecule chaperones for protein misfolding diseases.